High-resolution analysis of genomic copy number alterations in bladder cancer by microarray-based comparative genomic hybridization

被引:117
作者
Hurst, CD
Fiegler, H
Carr, P
Williams, S
Carter, NP
Knowles, MA
机构
[1] St James Univ Hosp, Canc Res UK Clin Ctr, Leeds LS9 7TF, W Yorkshire, England
[2] Wellcome Trust Sanger Inst, Sanger Inst Canc Res UK Genom Microarray Grp, Cambridge CB10 1SA, England
关键词
bladder cancer; comparative genomic hybridization; array;
D O I
10.1038/sj.onc.1207260
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
We have screened 22 bladder tumour- derived cell lines and one normal urothelium- derived cell line for genome- wide copy number changes using array comparative genomic hybridization ( CGH). Comparison of array CGH with existing multiplex-fluorescence in situ hybridization ( M-FISH) results revealed excellent concordance. Regions of gain and loss were defined more accurately by array CGH, and several small regions of deletion were detected that were not identified by M- FISH. Numerous genetic changes were identified, many of which were compatible with previous results from conventional CGH and loss of heterozygosity analyses on bladder tumours. The most frequent changes involved complete or partial loss of 4q ( 83%) and gain of 20q ( 78%). Other frequent losses were of 18q ( 65%), 8p ( 65%), 2q ( 61%), 6q ( 61%), 3p ( 56%), 13q ( 56%), 4p ( 52%), 6p ( 52%), 10p ( 52%), 10q ( 52%) and 5p ( 43%). We have refined the localization of a region of deletion at 8p21.2- p21.3 to an interval of approximately 1 Mb. Five homozygous deletions of tumour suppressor genes were confirmed, and several potentially novel homozygous deletions were identified. In all, 15 high- level amplifications were detected, with a previously reported amplification at 6p22.3 being the most frequent. Real- time PCR analysis revealed a novel candidate gene with consistent overexpression in all cell lines with the 6p22.3 amplicon.
引用
收藏
页码:2250 / 2263
页数:14
相关论文
共 64 条
  • [1] Alteration of the PATCHED locus in superficial bladder cancer
    Aboulkassim, TO
    LaRue, H
    Lemieux, P
    Rousseau, F
    Fradet, Y
    [J]. ONCOGENE, 2003, 22 (19) : 2967 - 2971
  • [2] Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene
    Albertson, DG
    Ylstra, B
    Segraves, R
    Collins, C
    Dairkee, SH
    Kowbel, D
    Kuo, WL
    Gray, JW
    Pinkel, D
    [J]. NATURE GENETICS, 2000, 25 (02) : 144 - 146
  • [3] Somatic mutation of PTEN in bladder carcinoma
    Aveyard, JS
    Skilleter, A
    Habuchi, T
    Knowles, MA
    [J]. BRITISH JOURNAL OF CANCER, 1999, 80 (5-6) : 904 - 908
  • [4] Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors
    Billerey, C
    Chopin, D
    Aubriot-Lorton, MH
    Ricol, D
    de Medina, SGD
    Van Rhijn, B
    Bralet, MP
    Lefrere-Belda, MA
    Lahaye, JB
    Abbou, CC
    Bonaventure, J
    Zafrani, ES
    van der Kwast, T
    Thiery, JP
    Radvanyi, F
    [J]. AMERICAN JOURNAL OF PATHOLOGY, 2001, 158 (06) : 1955 - 1959
  • [5] Bohm M, 1997, INT J CANCER, V74, P291
  • [6] Bringuier PP, 1996, ONCOGENE, V12, P1747
  • [7] Bruch J, 1998, GENE CHROMOSOME CANC, V23, P167, DOI 10.1002/(SICI)1098-2264(199810)23:2<167::AID-GCC10>3.0.CO
  • [8] 2-L
  • [9] Bruch J, 2000, CANCER RES, V60, P4526
  • [10] CAIRNS P, 1993, ONCOGENE, V8, P1083